Abstract
Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Current Pharmaceutical Design
Title: The Ultra High Risk Approach to Define Psychosis Risk
Volume: 18 Issue: 4
Author(s): Alison R. Yung, Paolo Fusar-Poli and Barnaby Nelson
Affiliation:
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Abstract: Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Export Options
About this article
Cite this article as:
R. Yung Alison, Fusar-Poli Paolo and Nelson Barnaby, The Ultra High Risk Approach to Define Psychosis Risk, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316299
DOI https://dx.doi.org/10.2174/138161212799316299 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic issue: Soluble Beta Amyloid in a Continuum from Physiology to Pathology: Searching the Determinants of its Effects and Designing New Pharmacological Treatments)
Current Pharmaceutical Design Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Development of Small-Molecule Inhibitors of Raf
Recent Patents on Anti-Infective Drug Discovery "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Progress and Promise of Nur77-based Therapeutics for Central Nervous System Disorders
Current Neuropharmacology Aquaporins and Glia
Current Neuropharmacology Episodic Memory Impairment in Frontotemporal Dementia; A <sup>99m</sup>Tc- HMPAO SPECT Study
Current Alzheimer Research Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics <i>Lactobacillus Rhamnosus</i> UBLR-58 and Diclofenac Potentiate the Anti- Alzheimer Activity of Curcumin in Mice
Current Enzyme Inhibition Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology The Neuropharmacology of Cluster Headache and other Trigeminal Autonomic Cephalalgias
Current Neuropharmacology Osteoprotegerin in Cardiovascular Disease: Ally or Enemy?
Current Pharmaceutical Design Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Subject Index To Volume 7
Current Drug Targets Nanoparticles, Neurotoxicity and Neurodegenerative Diseases
Current Drug Metabolism Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy
Current HIV Research Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology